Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841509 | 0.82 | CES2 (0.65) | CES2CES1GSK3BPTPN1ACP3 | |
| SCHEMBL7448575 | 0.82 | GSK3B (0.53) | CES2CES1GSK3BPTPN1ACP3 | |
| SCHEMBL9280969 | 0.81 | GSK3B (0.52) | CES2CES1GSK3BPTPN1ACP3 | |
| SCHEMBL29099863 | 0.79 | CES2 (0.53) | CES2ACP3SRD5A2CYP1A2 | |
| SCHEMBL9558033 | 0.78 | HDAC3 (0.44) | CES2CES1PTPN1 | |
| SCHEMBL840763 | 0.77 | GSK3B (0.47) | CES2CES1GSK3BEPHX2CNR2 | |
| SCHEMBL17633670 | 0.75 | CYP1A2 (0.45) | CES2CES1CYP1A2 | |
| SCHEMBL9298515 | 0.75 | BRD4 (0.45) | CES2CES1GSK3BCNR2CYP1A2 | |
| SCHEMBL75858 | 0.75 | BRD4 (0.45) | CES2CES1GSK3BCNR2CYP1A2 | |
| SCHEMBL10465540 | 0.75 | GSK3B (0.59) | CES2CES1GSK3BPTPN1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197900-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9969752-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3197900-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2331498-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2331498-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| WO-2016049099-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-9096521-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021882-A2 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021882-A2 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048619-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048619-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048619-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | CES2 997/4885CES1 1074/4885GSK3B 2760/4885 |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | CES2 3080/4885CES1 959/4885GSK3B 1132/4885 |
| US-20100048619-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM5 | CES2 949/4885CES1 773/4885GSK3B 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.